NNNN (Anbio Biotechnology) Earnings Power Value (EPV): $1.53 (As of Dec25)


NNNN Anbio Biotechnology NNNN
24 GF Score
Price $12.46
! 2 Warning Signs
View Full Analysis

What is Anbio Biotechnology Earnings Power Value (EPV)?

Anbio Biotechnology NNNN +2.88% 24 Earnings Power Value (EPV) is $1.53 as of Dec25. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

As of Dec25, Anbio Biotechnology's earnings power value is $1.53. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


Anbio Biotechnology  (NAS:NNNN) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


Anbio Biotechnology Earnings Power Value (EPV) Related Terms


Anbio Biotechnology Earnings Power Value (EPV) Historical Data

* Premium members only.

The historical data trend for Anbio Biotechnology's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anbio Biotechnology Earnings Power Value (EPV) Chart

Anbio Biotechnology Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Earnings Power Value (EPV)
0.00 0.00 0.00 0.00 0.00

Anbio Biotechnology Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Earnings Power Value (EPV) Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

NNNN vs ANGO, OSUR, UTMD: Earnings Power Value (EPV) Comparison

For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anbio Biotechnology Earnings Power Value (EPV) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Anbio Biotechnology's Earnings Power Value (EPV) falls into.


NNNN
24GF Score
Anbio Biotechnology NNNN
Earnings Power Value (EPV) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anbio Biotechnology Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

Anbio Biotechnology's "Earning Power" Calculation:

Average of Last 5 Years Last Year
Revenue 10.30
DDA 0.00
Operating Margin % 43.81
SGA * 25% 0.43
Tax Rate % 0.00
Maintenance Capex 0.00
Cash and Cash Equivalents 11.90
Short-Term Debt 0.00
Long-Term Debt 0.00
Shares Outstanding (Diluted) 43.67

1. Start with "Earnings" not including accounting adjustments (one-time charges not excluded unless policy has changed). "Earnings" are "Operating Income.

2. Look at average margins over a business/Industry cycle: Average Operating Margin = 43.81%

To normalize margins and eliminate the effects on profitability of valuing the firm at different points in the business cycle, it is usually best to take a long-term average of operating margins. Ideally this would be as long as 10 years and include at least one economic downturn. However, since most of companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year margin.

3. Multiply average margins by sustainable revenues and then adjust for maintenance SGA. This yields "normalized" EBIT:

To be conservative, GuruFocus uses an average of the 5 year revenues as the sustainable revenue.
EPV analysis recognises that part of SG&A expenditure is made to maintain and replace the existing assets, while part is made to grow sales. Since EPV is only interested in what it costs a going concern to maintain its existing asset base, it adds back a percentage of SG&A (between 15% and 50% - this is a matter of judgment and industry knowledge) to make up for the fact that some of this expenditure went to fund growth and shouldn't be accounted for. To start off, we assume 25% for the sake of prudence.
Sustainable Revenue = $10.30 Mil, Average Operating Margin = 43.81%, Average Adjusted SGA = 0.43,
therefore "Normalized" EBIT = Sustainable Revenue * Average Operating Margin + Average Adjusted SGA = 10.30 * 43.81% +0.43 = $4.940831676 Mil.

4. Multiply by one minus Average Tax Rate (NOPAT):

Same as average operating margin calculation, GuruFocus takes an average of the 5 years tax rates.
Average Tax Rate = 0.00%, and "Normalized" EBIT = $4.940831676 Mil,
therefore After-tax "Normalized" EBIT = "Normalized" EBIT * ( 1 - Average Tax Rate ) = 4.940831676 * ( 1 - 0.00% ) = $4.940831676 Mil.

5. Add back Excess Depreciation (after tax at 1/2 average tax rate). This yields "normalized" Earnings:

Excess Depreciation = Average DDA * % of Excess Depreciation (after tax at 1/2 average tax rate) = 0.00 * 0.5 * 0.00% = $0 Mil.
"Normalized" Earnings = After-tax "Normalized" EBIT + Excess Depreciation = 4.940831676 + 0 = $4.940831676 Mil.

6. Adjusted for Maintenance Capital Expenditure:

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Third, calculate Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
Fourth, GuruFocus uses an average of the 5 year maintenance capital expenditures as maintenance CAPEX.
Anbio Biotechnology's Average Maintenance CAPEX = $0.00 Mil *.
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

7. Investors require a return of "WACC" for the risk they are taking: WACC = 9%

8. Anbio Biotechnology's current cash and cash equivalent = $11.90 Mil.
Anbio Biotechnology's current interest bearing debt = Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation = 0.00 + 0.00 = $0 Mil.
Anbio Biotechnology's current Shares Outstanding (Diluted Average) = 43.67 Mil.

Anbio Biotechnology's Earnings Power Value (EPV) for Dec25 is calculated as:

EPV = ( ( Norm. Earnings-Maint. CAPEX *) / WACC + CashandEquiv - Int. Bearing Debt ) / Shares Outstanding (Diluted Average)
= ( ( 4.940831676 - 0.00)/ 9%+11.90-0 )/43.67
=1.53

Margin of Safety (EPV)=( Earnings Power Value (EPV)-Current Price )/Earnings Power Value (EPV)
=( 1.5295642455883-12.46 )/1.5295642455883
= -714.61%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

What does a Earnings Power Value (EPV) of $1.53 mean?
Anbio Biotechnology (NNNN) has a Earnings Power Value (EPV) of $1.53 as of Dec25. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Anbio Biotechnology and its competitors.
Is Anbio Biotechnology's Earnings Power Value (EPV) too high?
Anbio Biotechnology's current Earnings Power Value (EPV) is $1.53. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's Earnings Power Value (EPV) compare to ANGO and OSUR?
Anbio Biotechnology's Earnings Power Value (EPV) of $1.53 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Power Value (EPV) for a Medical Devices & Instruments company?
A good Earnings Power Value (EPV) depends on the Medical Devices & Instruments industry context. However, Earnings Power Value (EPV) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Power Value (EPV) mean?
A high Earnings Power Value (EPV) can signal that a stock is expensive relative to its fundamentals. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Anbio Biotechnology and its competitors. Anbio Biotechnology's current Earnings Power Value (EPV) is $1.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current Earnings Power Value (EPV) of $1.53. The current Earnings Power Value (EPV) is $1.53. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Power Value (EPV) calculated?
Earnings Power Value (EPV) is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current Earnings Power Value (EPV) is $1.53 as of Dec25. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anbio Biotechnology Business Description

Address Friedrich-Ebert-Anlage 35-37, Frankfurt am Main, HE, DEU, 60327
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score

Get the complete analysis for NNNN

Earnings Power Value (EPV) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.46
Price